Capitalizing on Success

Feature
Article
Pharmaceutical TechnologyPharmaceutical Technology, November 2023
Volume 47
Issue 11
Pages: 10

Industry investments indicate increasing trust in the newest modalities, including mRNA approaches.

High Angle Shot of a Working Desk of an Successful Person in Office with Cityscape Window View. | Image credit: © Gorodenkoff - stock.adobe.com

High Angle Shot of a Working Desk of an Successful Person in Office with Cityscape Window View. | Image credit: © Gorodenkoff - stock.adobe.com

As of mid-October 2023, there were 9342 clinical trial studies targeting COVID-19 (1). This is alongside 12,086 patents that relate to COVID-19 (2). Messenger RNA (mRNA) clinical trials, however, stand at only 483, with 112 related patents. mRNA was the talk of the industry during October 2023, as Katalin Karikó and Drew Weissman were awarded the Nobel Prize in Physiology or Medicine for their work in mRNA vaccines against COVID-19.
In an interview with Pharmaceutical Technology®, Laks Pernenkil, Principal and Practice Leader, US Life Sciences, Deloitte, pointed to “an emphasis coming out of the pandemic on supply resilience … with all the ups and downs around the supply of raw materials, there has been significant focus on ensuring patients are not affected by supply shortages, part of the anxiety has manifested around inflation [rising costs] of raw materials.” Pernenkil also drew attention to increased digitalization as improving process design, supply performance, and eventually, profits (3).
At the other end of the spectrum, discovering new types of drugs and therapies, the top five pharmaceutical companies’ investments in R&D in 2022 were Roche with $14.78 Billion, J&J $14.14 billion, Pfizer $12.38 billion, Merck $11.84, and BMS $10.02 billion, ranging between 15% to 30% of income (4). Such investment speaks of self-confidence and perhaps aligns with increasing trust in the newest modalities, including mRNA approaches.

References

  1. NIH. https://clinicaltrials.gov. Clinical trials.gov (accessed Oct. 12, 2023).
  2. World Health Organization, WHO’s Covid-19 Response Timeline (accessed Oct. 12, 2023).
  3. Playter, G. The Era of Digital Data in Bio/Pharma Manufacturing. PharmTech.com. Oct. 9, 2023.
  4. Statista. Leading 50 Global Pharmaceutical Companies by Prescription Sales and R&D Spending in 2022. Statista (accessed Oct. 12, 2023).

Article details

Pharmaceutical Technology
Vol. 47, No. 11
November 2023
Page: 10

Citation

When referring to this article, please cite it as Hennessy, M. Capitalizing on Success. Pharmaceutical Technology 2023 47 (11).

Recent Videos
Ian Lafferty from Upperton discusses the trends and challenges facing sterile manufacturing and how partnering with CDMOs can help innovators progress to the market.
Miguel Forte from ISCT and Kiji Therapeutics talks about the potential impact of a changing European political landscape.
Miguel Forte from ISCT and Kiji Therapeutics provides his insights into the changing political landscape in the US as well as legislative and regulatory adjustments
Miguel Forte from ISCT and Kiji Therapeutics chats about expectations for 2025 and the future technology agenda for industry.
Sheryl Johnson from Orbia Fluor & Energy Materials chats about gender diversity, how women are helping to advance innovation, sustainability challenges, and progress in the field of inhaled drugs.
Mike Baird from Schlafender Hase gives his predictions for how AI and ML may find use in the industry moving forwards and provides some predictions about M&A and the changing US government administration.
Mike Baird from Schlafender Haser discusses industry trends from 2024 and those expected to have an impact in 2025 from the perspective of a software developer.
Preeya Beczek from Beczek.COM gives her thoughts on the areas to watch with the new US administration and how Europe might be finalizing preparations for previous legislative changes
Related Content